Assessment of Brain Tumor Response: RANO and Its Offspring

Opinion StatementTreatment options for most nervous system tumors remain limited and patients are often confronted with significant morbidity and reduced life expectancy. However, significant efforts are underway to find more effective therapies for patients with primary and secondary brain tumors. As more and more clinical trials for nervous system tumors are being conducted, it is increasingly important to optimize the conduct of clinical trials in neuro-oncology. One of the key aspects in this regard is the development of objective and standardized criteria that allow for accurate response assessment in clinical trials and prevent the misclassification of responders and non-responders. Such misclassification may lead to premature discontinuation of an actually effective agent, thereby withholding a potentially active treatment from the patient. Conversely, patients may be inappropriately continued on an inactive treatment. Moreover, such misclassification may confound the data obtained in such studies and may lead to false conclusions with regards to the efficacy of the investigated drug. Therefore, reliable response assessment criteria are necessary that not only accurately capture radiographic changes but also account for treatment-related changes and incorporate the assessment of clinical status and quality of life (QoL). The Response Assessment in Neuro-Oncology (RANO) working group is an international collaboration of neuro-oncologists, medical oncologists, radiation oncologists, neurosurgeons, neuroradiologists, and regulatory groups (among others) commissioned to develop objective and tumor-specific response criteria for various tumor subtypes. This article reviews the currently available response criteria for high-grade glioma, low-grade glioma, and brain metastases and discusses some of the barriers to accurate assessment of treatment response in neuro-oncology.

[1]  Susan M. Chang,et al.  Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group. , 2015, The Lancet. Oncology.

[2]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[3]  P. Wen,et al.  Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. , 2014, Neuro-oncology.

[4]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[5]  K. Jaeckle.  Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment. , 2006, Seminars in oncology.

[6]  M. Rathbone,et al.  Postoperative contrast enhancement in patients with brain tumor , 1985, Annals of neurology.

[7]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[8]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[9]  Yi Lin,et al.  Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. , 2010, Neuro-oncology.

[10]  N. Lin,et al.  Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer , 2008, Cancer.

[11]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Uhm.  Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group , 2010 .

[13]  T. Cloughesy,et al.  NIMG-24HIGH SPATIOTEMPORAL DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI USING MULTIBAND ECHOPLANAR IMAGING (MB-EPI) , 2015 .

[14]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[15]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[16]  B. Cho,et al.  Nivolumab in NSCLC: latest evidence and clinical potential , 2015, Therapeutic advances in medical oncology.

[17]  Marion Smits,et al.  Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. , 2015, Neuro-oncology.

[18]  Timothy F Cloughesy,et al.  Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. , 2008, Neuro-oncology.

[19]  B. Hamm,et al.  Intra- and Interobserver Variability of Linear and Volumetric Measurements of Brain Metastases Using Contrast-Enhanced Magnetic Resonance Imaging , 2010, Investigative radiology.

[20]  L Junck,et al.  Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. , 2011, The Lancet. Oncology.

[21]  Dieta Brandsma,et al.  Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.

[22]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[23]  P. Wen,et al.  Response criteria for glioma , 2008, Nature Clinical Practice Oncology.

[24]  M. Gilbert,et al.  Bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[25]  M. Glantz,et al.  Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis , 2010, Cancer.

[26]  P. Wen,et al.  Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. , 2015, Neuro-oncology.

[27]  Susan M. Chang,et al.  Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. , 2013, The Lancet. Oncology.

[28]  M. J. van den Bent,et al.  Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Michael A. Finn,et al.  Transient postictal MRI changes in patients with brain tumors may mimic disease progression. , 2007, Surgical neurology.

[30]  M. Westphal,et al.  Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. , 2000, Neoplasia.

[31]  Susan M. Chang,et al.  Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma , 2009, Journal of Neuro-Oncology.

[32]  J. P. Glass,et al.  Leptomeningeal metastasis , 1993, Neurology.

[33]  R. Hitchins,et al.  A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Bradley J Erickson,et al.  Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. , 2006, Neuro-oncology.

[35]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[36]  P. Wen,et al.  Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression , 2009, Journal of Neuro-Oncology.

[37]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  P. Wen,et al.  Bevacizumab for recurrent malignant gliomas , 2008, Neurology.

[39]  A. Norden,et al.  Atypical and anaplastic meningiomas treated with bevacizumab , 2012, Journal of Neuro-Oncology.

[40]  J. Crowley,et al.  Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Katrina H. Smith,et al.  Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma , 2015, Neurology.

[42]  Patrick Y Wen,et al.  End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[44]  Dieta Brandsma,et al.  Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide , 2008, Cancer.

[45]  D. Silbergeld,et al.  Early postoperative magnetic resonance imaging following nonneoplastic cortical resection. , 1996, Journal of neurosurgery.

[46]  J. Henson,et al.  Brain Tumor Imaging in Clinical Trials , 2008, American Journal of Neuroradiology.

[47]  P. Wen,et al.  Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. , 2014, Neuro-oncology.

[48]  H. Rugo,et al.  Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER , 2011, Clinical Cancer Research.

[49]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[50]  J. Cairncross,et al.  Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Jill S. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012 , 2015, Neuro-oncology.

[52]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[53]  V. Smith,et al.  Therapeutic irradiation and brain injury. , 1980, International journal of radiation oncology, biology, physics.

[54]  J. Buckner,et al.  The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. , 2007, Neuro-oncology.

[55]  P. Allavena,et al.  Glucocorticoids affect human dendritic cell differentiation and maturation. , 1999, Journal of immunology.

[56]  T. Cloughesy,et al.  Bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[57]  J. Trapani,et al.  The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. , 2011, Blood.

[58]  Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens , 2011, British Journal of Cancer.

[59]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[60]  M. Prados,et al.  Challenges with defining response to antitumor agents in pediatric neuro‐oncology: A report from the response assessment in pediatric neuro‐oncology (RAPNO) working group , 2013, Pediatric blood & cancer.

[61]  J. Dietrich,et al.  Cerebral radiation necrosis: diagnostic challenge and clinical management. , 2015, Revista de neurologia.

[62]  Andrew D Norden,et al.  Response Assessment Challenges in Clinical Trials of Gliomas , 2010, Current oncology reports.

[63]  A. Brandes,et al.  MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  Naoya Hashimoto,et al.  Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. , 2015, The Lancet. Oncology.

[65]  Raymond Y Huang,et al.  Pitfalls in the Neuroimaging of Glioblastoma in the Era of Antiangiogenic and Immuno/Targeted Therapy – Detecting Illusive Disease, Defining Response , 2015, Front. Neurol..

[66]  S. Phuphanich,et al.  Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Martin Bendszus,et al.  Response assessment criteria for brain metastases: proposal from the RANO group. , 2015, The Lancet. Oncology.

[68]  Tracy T Batchelor,et al.  Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. , 2006, Neuro-oncology.

[69]  J. Raizer,et al.  Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. , 2015, Journal of neurosurgery.

[70]  D. Ettinger,et al.  Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  R. Gonzalez,et al.  Clinical and radiographic features of peritumoral infarction following resection of glioblastoma , 2006, Neurology.

[72]  Susan M. Chang,et al.  Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. , 2013, The Lancet. Oncology.

[73]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[74]  Susan M. Chang,et al.  Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). , 2014, Neuro-oncology.